Interleukin 17F

From Wikipedia, the free encyclopedia
  (Redirected from )
IL17F
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesIL17F, CANDF6, IL-17F, ML-1, ML1, interleukin 17F, IL17A
External IDsOMIM: 606496 MGI: 2676631 HomoloGene: 17115 GeneCards: IL17F
Orthologs
SpeciesHumanMouse
Entrez

112744

257630

Ensembl

ENSG00000112116

ENSMUSG00000041872

UniProt

Q96PD4

Q7TNI7

RefSeq (mRNA)

NM_052872
NM_172343

NM_145856

RefSeq (protein)

NP_443104

NP_665855

Location (UCSC)Chr 6: 52.24 – 52.24 MbChr 1: 20.85 – 20.86 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interleukin 17F (IL-17F) is signaling protein that is in human is encoded by the IL17F gene and is considered a pro-inflammatory cytokine. This protein belongs to the interleukin 17 family and is mainly produced by the T helper 17 cells after their stimulation with interleukin 23. However, IL-17F can be also produced by a wide range of cell types, including innate immune cells and epithelial cells.[5][6][7][8]

The IL17F gene is located on chromosome 6p12 and was discovered in 2001. This cytokine can be secreted as disulfide-linked homodimer or heterodimer.[9][10]

Function and signaling[]

IL-17F is involved in the development of inflammation and host defense against infection by inducing the expression of genes that encode other proinflammatory cytokines, such as tumor necrosis factor, interleukin 1, interleukin 6 and some members of the colony-stimulating factor family. IL-17F can also induce expression of chemokines, such as CXCL1, CXCL5, interleukin 8, CCL7 and others, thereby promoting inflammation and neutrophil recruitment. IL-17F signaling can also lead to antimicrobial peptide and matrix metalloproteinase production. The target cells of IL-17F are epithelial cells, fibroblasts, keratinocytes, synoviocytes and endothelial cells. These cells express IL-17RA and IL-17RC, which are the receptors IL-17F binds. IL-17F shows a broad tissue expression pattern, including the lungs, where it may be associated with the pathogenesis of asthma. IL-17F employs Act1[clarification needed] and TRAF6 as its signal transducers to induce the expression of the pro-inflammatory cytokines and chemokines in many different cell types. IL-17F signaling also activates the MAP kinase pathway and leads to the activation of NF-κB, MAPK-AP-1 and C/EBP.[7][9][11]

IL-17F is highly (55%) homologous to interleukin-17A (IL-17A). These two molecules bind to the same receptors and are very likely to have similar biological functions. IL-17A and IL-17F are often co-expressed. However, IL-17F is a weaker inducer of pro-inflammatory cytokine expression and is produced by a wider range of cell types than IL-17A. Another difference lies in the binding affinities for their receptors: IL-17A binds more strongly to IL-17RA, IL-17F to IL-17RC.[7][12][13]

The interleukin 17 family members are among the effector cytokines of Th17 immune response. This immune response protects hosts from pathogens at epithelial and mucosal tissues including the skin, lung, and intestine. The Th17-type immune response is directed primarily against extracellular bacteria. IL-17F as an effector cytokine of Th17 cells is involved in host defense against bacterial infections. It has many mechanisms by which it helps resist bacteria. IL-17F has the ability to stimulate the production of defensins and other antimicrobial peptides; it can also resist bacteria through production of pro-inflammatory cytokines and chemokines that attract neutrophils and other effector cells.[7][14]

Clinical significance[]

IL-17F is a proinflammatory cytokine associated with many diseases. It very often plays crucial role in autoimmune diseases.

One of the diseases associated with IL-17F is psoriasis. Levels of IL-17F, as well as the levels of IL-17A, are increased in psoriatic skin and in synovial cells in psoriatic arthritis. IL-17F is capable of inducing cartilage matrix release and can inhibit the synthesis of new cartilage matrix. The monoclonal antibody bimekizumab against IL-17A and IL-17F is approved in Europe for the treatment of psoriasis; it may also be useful in the treatment of ankylosing spondylitis.[15][16]

IL-17F plays an important role in asthma and allergic airway inflammation. IL-17F has been well characterized both in vitro and in vivo to have a pro-inflammatory role in asthma. IL-17F was originally found in bronchoalveolar lavage cells from patients with allergic asthma upon ragweed allergen stimulation. The expression level of IL-17F correlates with the severity of the disease. Overexpression of this cytokine in the airway is associated with neutrophilia, secretion of many cytokines, increased airway activity and mucus hypersecretion.[9]

IL-17F is also involved in the pathogenesis of intestinal inflammation. Expression of IL-17F in colon is associated with inflammatory bowel disease, and this inducible IL-17F expression is significantly higher in Crohn's disease than in ulcerative colitis.[11][16]

Increased expression of IL-17F is also found in neuronal inflammation—specifically, in active lesion sites in experimental autoimmune encephalitis, an animal model of multiple sclerosis. IL-17F together with IL-17A contributes to chronic inflammation.[16]

IL-17F may also be involved in tumorigenesis and associated with the tumor microenvironment (TME), as pro-tumor and anti-tumor functions have been ascribed to the related protein IL-17A has. However, a role for IL-17F in tumor development has not been well described.[7]

References[]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000112116 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000041872 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Linares-Pineda, Teresa María; Cañadas-Garre, Marisa; Sánchez-Pozo, Antonio; Calleja-Hernández, Miguel Ángel (November 2016). "Gene polymorphisms as predictors of response to biological therapies in psoriasis patients". Pharmacological Research. 113 (Pt A): 71–80. doi:10.1016/j.phrs.2016.07.020. PMID 27524442.
  6. ^ Moseley, T.A.; Haudenschild, D.R.; Rose, L.; Reddi, A.H. (April 2003). "Interleukin-17 family and IL-17 receptors". Cytokine & Growth Factor Reviews. 14 (2): 155–174. doi:10.1016/S1359-6101(03)00002-9. PMID 12651226.
  7. ^ a b c d e Iwakura, Yoichiro; Ishigame, Harumichi; Saijo, Shinobu; Nakae, Susumu (February 2011). "Functional Specialization of Interleukin-17 Family Members". Immunity. 34 (2): 149–162. doi:10.1016/j.immuni.2011.02.012. PMID 21349428.
  8. ^ McGeachy, Mandy J.; Cua, Daniel J.; Gaffen, Sarah L. (April 2019). "The IL-17 Family of Cytokines in Health and Disease". Immunity. 50 (4): 892–906. doi:10.1016/j.immuni.2019.03.021. PMC 6474359. PMID 30995505.
  9. ^ a b c Kawaguchi, Mio; Kokubu, Fumio; Fujita, Junichi; Huang, Shau-Ku; Hizawa, Nobuyuki (2009-12-01). "Role of Interleukin-17F in Asthma". Inflammation & Allergy Drug Targets. 8 (5): 383–389. doi:10.2174/1871528110908050383. PMID 20025586.
  10. ^ Gorczynski, R. M. (2020), Birbrair, Alexander (ed.), "IL-17 Signaling in the Tumor Microenvironment", Tumor Microenvironment, Advances in Experimental Medicine and Biology, Cham: Springer International Publishing, vol. 1240, pp. 47–58, doi:10.1007/978-3-030-38315-2_4, ISBN 978-3-030-38314-5, PMID 32060887, S2CID 211122697, retrieved 2021-06-30
  11. ^ a b Chang, Seon Hee; Dong, Chen (April 2009). "IL-17F: Regulation, signaling and function in inflammation". Cytokine. 46 (1): 7–11. doi:10.1016/j.cyto.2008.12.024. PMC 2663007. PMID 19233684.
  12. ^ Ho, Allen W.; Shen, Fang; Conti, Heather R.; Patel, Nayan; Childs, Erin E.; Peterson, Alanna C.; Hernández-Santos, Nydiaris; Kolls, Jay K.; Kane, Lawrence P.; Ouyang, Wenjun; Gaffen, Sarah L. (2010-06-16). "IL-17RC Is Required for Immune Signaling via an Extended SEF/IL-17R Signaling Domain in the Cytoplasmic Tail". The Journal of Immunology. 185 (2): 1063–1070. doi:10.4049/jimmunol.0903739. ISSN 0022-1767. PMC 2897912. PMID 20554964.
  13. ^ Akimzhanov, Askar M.; Yang, Xuexian O; Dong, Chen (March 2007). "Chromatin Remodeling of Interleukin-17 (IL-17)-IL-17F Cytokine Gene Locus during Inflammatory Helper T Cell Differentiation". Journal of Biological Chemistry. 282 (9): 5969–5972. doi:10.1074/jbc.c600322200. ISSN 0021-9258. PMID 17218320.
  14. ^ Zhang, Xiaoping; Angkasekwinai, Pornpimon; Dong, Chen; Tang, Hong (January 2011). "Structure and function of interleukin-17 family cytokines". Protein & Cell. 2 (1): 26–40. doi:10.1007/s13238-011-1006-5. ISSN 1674-800X. PMC 4875287. PMID 21337007.
  15. ^ Reis, Joel; Vender, Ron; Torres, Tiago (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–399. doi:10.1007/s40259-019-00361-6. ISSN 1173-8804. PMID 31172372. S2CID 174812750.
  16. ^ a b c Seiderer, Julia; Elben, Ira; Diegelmann, Julia; Glas, Jürgen; Stallhofer, Johannes; Tillack, Cornelia; Pfennig, Simone; Jürgens, Matthias; Schmechel, Silke; Konrad, Astrid; Göke, Burkhard (April 2008). "Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohnʼs disease and analysis of the IL17F p.His161Arg polymorphism in IBD". Inflammatory Bowel Diseases. 14 (4): 437–445. doi:10.1002/ibd.20339. ISSN 1078-0998. PMID 18088064. S2CID 24783597.
Retrieved from ""